



September 9, 2019



LATEST NEWS




The Most Important U.S. Patent Cases of 2019 Thus Far

By: [Christopher Loh](#)

Thus far 2019 has been an eventful year for patent law in the United States. Over the past seven months, the U.S. Supreme Court and the Court of Appeals for the Federal Circuit (the U.S. appellate court tasked with reviewing all district court patent decisions) have issued several significant rulings that may affect the rights of patent owners. This article

reviews the most important of these rulings.



Spotlight On: Biosimilar Litigations

Spotlight On: Rituxan[®] (rituximab) / Truxima[®] (rituximab-abbs) / Ruxience[®] (rituximab-pvvr)

Spotlight On: Humira[®] (adalimumab) / Amjevita[™] (adalimumab-atto) / Cyltezo[®] (adalimumab-adbm) / Hyrimoz[™] (adalimumab-adaz) / Hadlima[™] (adalimumab-

bwwd)

Spotlight On: Enbrel[®] (etanercept) / Erelzi[®] (etanercept-szsz) / Eticovo[™] (etanercept-ykro)

Spotlight On: Lantus[®] / Lantus[®] SoloSTAR[®] (insulin glargine recombinant) / Basaglar[®] (insulin glargine)

BiologicsHQ's "Spotlight On" product dashboards provide, at a glance, an overview of the status of U.S. patent proceedings. The dashboards concerning rituximab ([Rituxan[®]](#), [Truxima[®]](#), and [Ruxience[®]](#)),

adalimumab ([Humira®](#), [Amjevita™](#), [Cyltezo®](#), [Hyrimoz™](#), and [Hadlima™](#)), etanercept ([Enbrel®](#), [Erelzi®](#), and [Eticovo™](#)), and insulin glargine ([Lantus®](#) / [Lantus® SoloSTAR®](#) and [Basaglar®](#)) have been updated with activity through August 31, 2019.

BiologicsHQ's "Spotlight On Biosimilar Litigations" dashboard provides, at a glance, an overview of the status of U.S. biosimilar patent litigations through August 31, 2019.

Read
More
News

UPDATES

IPRs and PGRs

Herceptin® (trastuzumab):

- On August 1, 2019, the USPTO Director filed a notice of intervention in Fed. Cir. Case No. 19-1265, appealing the final written decision in IPR2017-01960. [Hospira](#) and [Samsung Bioepis](#) previously terminated their involvement in the appeal.

Neupogen® (filgrastim) / Neulasta® (pegfilgrastim):

- On August 8, 2019, [Apotex](#) filed a motion for adverse judgment in PGR2019-0001. This does not affect the other petitioner [Adello](#), who will continue the proceeding as the sole petitioner.

Lantus® (insulin glargine recombinant):

- On August 15, 2019, IPRs filed by [Pfizer](#) were instituted and joined with IPRs previously filed by [Mylan](#), including:
 - IPR2019-00977 joined with IPR2018-01675
 - IPR2019-00978 joined with IPR2018-01676
 - IPR2019-00980 joined with IPR2018-01678
 - IPR2019-00981 joined with IPR2018-01679
 - IPR2019-00982 joined with IPR2019-00122
 - IPR2019-00987 joined with IPR2018-01684
 - IPR2019-00979 was instituted, but joinder with IPR2018-01670 was denied.
- On August 19, 2019, IPR2019-01022 filed by [Pfizer](#) was instituted and joined with IPR2018-01680 previously filed by [Mylan](#).
- On August 20, 2019, IPR2019-01023 filed by [Pfizer](#) was instituted and joined with IPR2018-01682 previously filed by [Mylan](#).

Soliris® (eculizumab):

- On August 30, 2019, IPR2019-00739, IPR2019-00740, and IPR2019-00741 filed by [Amgen](#) were instituted.

Litigations

Herceptin® (trastuzumab):

- On August 7, 2019, the Federal Circuit denied **Genentech's** request for an injunction against **Amgen** pending resolution of Fed. Cir. Case No. 19-2156 and **Genentech's** request to expedite the appeal.

Enbrel® (etanercept):


- On August 9, 2019, the District Court in **ImmuneX v. Sandoz**, Case No. 2:16-cv-01118 (D.N.J.), determined that claims 11-23 and 35-36 of U.S. Patent No. 8,063,182 and claims 3, 8, and 10 of U.S. Patent No. 8,163,522 were not invalid. The parties previously stipulated to infringement.

Praluent® (alirocumab) / Repatha® (evolocumab):


- On August 28, 2019, **Sanofi's** motion for judgment as a matter of law was denied as to written description, but granted as to enablement in Case No. 1:14-cv-01317 (D. Del.) (and consolidated cases 1:14-cv-01414 (D. Del.), 1:14-cv-01393 (D. Del.), and 1:14-cv-01349 (D. Del.)). Because the patent claims at issue were found to lack enablement, **Amgen's** motion for a permanent injunction was denied as moot.

STATISTICS


Biosimilar-Related IPR Petitions




Biosimilar-Related IPR Petitions by Fiscal Year




Biosimilar-Related IPR Petitions by Quarter




Biosimilar-Related IPRs by Reference Product




Biosimilar-Related IPRs: Number of Patents and Claims Challenged




Status of Biosimilar-Related IPRs




Biosimilar-Related IPRs: Institution and Final Written Decision Outcomes




Biosimilar-Related Litigations




Biosimilar-Related Litigations by Reference Product



Biosimilar-Related Litigations by Year



Patents Subject to Biosimilar-Related IPRs and Litigations




Biosimilars Approved in the United States

U.S. Brand Name	Reference Product	U.S. Approval Date	U.S. Approval Agency	U.S. Approval Type	U.S. Approval Status	U.S. Approval Date	U.S. Approval Agency	U.S. Approval Type	U.S. Approval Status
Adalimumab	Humira	2013	FDA	341	Approved	2013	EMA	341	Approved
Adalimumab	Humira	2014	FDA	341	Approved	2014	EMA	341	Approved
Adalimumab	Humira	2015	FDA	341	Approved	2015	EMA	341	Approved
Adalimumab	Humira	2016	FDA	341	Approved	2016	EMA	341	Approved
Adalimumab	Humira	2017	FDA	341	Approved	2017	EMA	341	Approved
Adalimumab	Humira	2018	FDA	341	Approved	2018	EMA	341	Approved
Adalimumab	Humira	2019	FDA	341	Approved	2019	EMA	341	Approved
Adalimumab	Humira	2020	FDA	341	Approved	2020	EMA	341	Approved
Adalimumab	Humira	2021	FDA	341	Approved	2021	EMA	341	Approved
Adalimumab	Humira	2022	FDA	341	Approved	2022	EMA	341	Approved


Biosimilar Applications Pending in the United States

Reference Product	U.S. Brand Name	U.S. Approval Date	U.S. Approval Agency	U.S. Approval Type	U.S. Approval Status
Adalimumab	Humira	2013	EMA	341	Approved
Adalimumab	Humira	2014	EMA	341	Approved
Adalimumab	Humira	2015	EMA	341	Approved
Adalimumab	Humira	2016	EMA	341	Approved
Adalimumab	Humira	2017	EMA	341	Approved
Adalimumab	Humira	2018	EMA	341	Approved
Adalimumab	Humira	2019	EMA	341	Approved
Adalimumab	Humira	2020	EMA	341	Approved
Adalimumab	Humira	2021	EMA	341	Approved
Adalimumab	Humira	2022	EMA	341	Approved


Biologic Drug IPR Petitions



Biologic Drug IPRs by Reference Product




Patents Subject to Biologic Drug IPRs and Litigations




Biologic Drugs Most Frequently Targeted in Serial IPR Challenges



Biologic Drug Patent Multiple IPR Challenges by Claim Type



Number of IPR Challenges Per Biologic Drug Patent



BiologicsHQ Search

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book. Product and Company page search results are reported for FDA-approved indications, aBLA and 505(b)(2) activity, approved foreign biosimilars, IPRs and U.S. litigations.

Contact the BiologicsHQ Team



Robert S. Schwartz, Ph.D.
Chair
+1 212.218.2298
RSchwartz@Venable.com



Ha Kung Wong
Partner
+1 212.218.2571
HWong@Venable.com

CALIFORNIA | DELAWARE | MARYLAND | NEW YORK | VIRGINIA | WASHINGTON, DC

© 2019 Venable LLP. This email is published by the law firm Venable LLP. It is not intended to provide legal advice or opinion. Such advice may only be given when related to specific fact situations that Venable has accepted an engagement as counsel to address. ATTORNEY ADVERTISING.

Venable.com | Manage Preferences | Unsubscribe | If you are having trouble viewing this email, click here to view it in the browser or contact us by mail at Venable LLP, 600 Massachusetts Avenue, NW, Washington, DC 20001.